12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Other News

Cleveland BioLabs, U.S. Department of Defense other news

Cleveland BioLabs received a $770,442 increase to its $1.6 million contract with the DoD's Defense Threat Reduction Agency (DTRA) issued in January 2011 to develop entolimod ( CBLB502) to treat acute radiation syndrome (ARS). The increase brings the total value of the contract to $2.4 million. The company already has a separate...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >